Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development.
about
A Review of Modeling Approaches to Predict Drug Response in Clinical OncologyClinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.Considerations for the prediction of survival time in pancreatic cancer based on registry data.Joint modeling tumor burden and time to event data in oncology trials.Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis.Missing data in model-based pharmacometric applications: points to consider.A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumabKnowledge management for efficient quantitative analyses during regulatory reviews.Resampling phase III data to assess phase II trial designs and endpoints.Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignanciesResampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsPopulation pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trialsClinical trials in the era of personalized oncology.Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With EribulinDisease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinModeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validationA Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors.A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib UseComparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.Modeling NSCLC progression: recent advances and opportunities availableWhen progressive disease does not mean treatment failure: reconsidering the criteria for progression.Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft miceBaseline tumour measurements predict survival in advanced non-small cell lung cancer.Estimation of renal cell carcinoma treatment effects from disease progression modelingModels of excellence: improving oncology drug development.PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
P2860
Q28066777-4B69B965-4E3C-43F8-AB88-E86D5FB052D6Q30542069-63509FB4-C3D2-4737-BC80-B76CAF0469B7Q30558610-4B95E7A5-D04A-4CCF-8E43-830FE8F2AAFBQ30654731-171F7A57-2DE0-4E85-B741-36640E4AE658Q30837595-F0E8E2C2-21D9-4D36-AB1A-8299301B420EQ31052763-640B7CBB-57F1-4D08-A552-DC97F36AB823Q33636321-336162B8-F12E-486E-A97F-49F9C85F2FA0Q33706156-B4FE2A53-4DE8-4069-9E56-205C257CE194Q33729213-EC6004A8-88B1-43BE-BAF8-9716EEB1376DQ33761681-836AD00C-EE5C-4E29-B795-32C390BE2186Q34082039-3ED387DF-F105-4088-9193-F1170513A8F1Q34144413-F4CAD440-ABC2-48BA-8094-EB8A7E51902FQ34348318-F020E3AF-BB3E-4C55-8711-3A781FEE4AA2Q34571048-C4D3DF96-EF49-4240-B6C8-8B4007432F2EQ34716556-C03FE3E1-E8A9-4FFA-976D-D447CEC9E5CEQ34953673-4F160F65-0DCB-4835-87A2-583BDE543589Q35016789-788FC274-345A-451B-83FC-727C5014CEA5Q35081379-DAEBBF69-AC81-4C44-83A4-0D0E0FBF82E2Q35168766-82FF0D3D-B960-47AA-8B8F-2ACFDE760351Q35375761-AF1DF64C-1E95-490D-9E85-7C50715FF9D8Q35555963-072B12F8-F85B-47E1-A00A-9FB28D7D5CA3Q35914787-A2E1838F-0F26-4DA3-AAAE-147CE8062AACQ35979543-B5FDE3BE-B15F-4286-A4A2-8EB2AC35A73CQ35979551-2D87CD06-F028-44BE-B4B2-9BCC03CE284AQ36076716-66350096-F447-478E-B909-D99D2BE2E705Q36232524-D98B5D00-DA17-4DC5-8ECF-68A7859702F9Q36276553-8D8B99D6-B957-4CD6-8A8E-1C04CE5D11FFQ36470125-2F05900F-5AA6-4034-8EA8-C57029E4A378Q36595762-D496AE03-4D07-46D2-B7D6-899460B42780Q36595921-5946A7F8-552A-45F0-99A7-E2F834350408Q36599208-2D403371-3712-4DE9-A487-68B527432D58Q36683248-68A36597-1F67-4E7B-8D0E-05D584A3AD74Q36693695-F5577F7E-C660-40D9-9CBE-1B0D44F4E973Q36910615-C9024FC3-97A5-4B47-9C01-FF9FEF7EBFB6Q37003248-96046D37-7325-45DB-BBEB-B4523AC2E4B6Q37067232-A64C3659-521E-4155-928D-4FF795BDE526Q37182213-8CD03035-A0AB-4168-B90E-DE06AC089CF5Q37217573-AC2085BC-D05E-48E5-BE71-9E6E0DC9A384Q37334405-AF110188-8238-4D09-8179-20125CF8477CQ37366059-9D5E00D0-A2E7-4BF3-A14B-7CDD3F30BCA9
P2860
Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Elucidation of relationship be ...... in clinical drug development.
@en
Elucidation of relationship be ...... in clinical drug development.
@nl
type
label
Elucidation of relationship be ...... in clinical drug development.
@en
Elucidation of relationship be ...... in clinical drug development.
@nl
prefLabel
Elucidation of relationship be ...... in clinical drug development.
@en
Elucidation of relationship be ...... in clinical drug development.
@nl
P2093
P2860
P356
P1476
Elucidation of relationship be ...... in clinical drug development.
@en
P2093
R Ramchandani
P2860
P304
P356
10.1038/CLPT.2009.64
P407
P577
2009-05-13T00:00:00Z